ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1003

Role of Particular Class I MHC Haplotypes in Determining Different Traits within the Psoriatic Arthritis Phenotypes

Muhammad Haroon1, Jon T. Giles2, Robert Winchester3 and Oliver M. FitzGerald1, 1Department of Rheumatology, Dublin Academic Medical Center, St. Vincent's University Hospital, Dublin, Ireland, 2Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, 3Dept of Medicine & Pathology, Columbia University, New York, NY

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Major histocompatibility complex (MHC) and psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Genetics and Genomics of Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose: A rigorously ascertained psoriatic arthritis (PsA) cohort demonstrated considerable genetic heterogeneity and provided preliminary evidence that MHC genes determine quantitative traits within the PsA phenotype with different patterns of MHC effect.

Methods: We now extend these findings by performing detailed clinical phenotyping of PsA cases to better characterize the clinical features associated with particular HLA class I alleles and their haplotypes. 

Results: A total of 150 PsA patients [mean age 52±12 years; 46% male; mean PsA duration=25±12 years; 45% with axial involvement; 25% with sacroiliitis; 41% with radiographic erosions; median PASI=1.2] were studied.  In univariate analysis, the inheritance of B*27:05 was apparently associated with a more severe joint disease phenotype including: joint erosions, the requirement for TNF therapy and axial disease manifestations such as spine involvement and sacroiliitis that were temporally preceded by or coincident with skin disease. In striking contrast, the presence of HLA-C*06, whether on a B*57-C*06 or B*37-C*06 haplotype, was associated with a considerable delay in the development of arthritis, and conferred a reciprocal phenotype of significant negative associations with arthritis severity, including the presence of erosions, the requirement for TNF inhibitor therapy, and axial disease. B*08 and B*08-C*07 (EH8.1) were correlated with joint deformities, erosions, TNF inhibitor requirement, osteolysis, and dactylitis, developing after the appearance of psoriasis, suggesting this haplotype denotes a more severe but delayed arthritic phenotype.

Surprisingly, in contrast to the uniform association of disease susceptibility with B*27, the association with phenotypic features was not uniform across all B*27 alleles, and was mainly accounted for by the B*27-C*01 (EH27.1) haplotype and not B*27-C*02 (EH27.2), suggesting the influence of additional genetic effects on EH27.1. The predictive value of these haplotypes was confirmed by logistic regression, which after adjustment for confounders showed, for example, the probability of developing sacroiliitis was almost completely determined by the inheritance of EH27.1, EH8.1 or C*05, figure A. Similarly, the probability of developing peripheral joint erosions was strongly associated with the presence of EH27.1, EH8.1 or C*03, figure B.

Conclusion: Certain HLA alleles, and, most strikingly particular haplotypes, contribute importantly to the magnitude of traits comprising the diverse phenotypes of PsA, but this contribution does not completely parallel the role of these alleles or haplotypes in determining susceptibility.


Disclosure:

M. Haroon,
None;

J. T. Giles,

Roche/Genentech,

5;

R. Winchester,
None;

O. M. FitzGerald,

Abbott Immunology Pharmaceuticals, Bristol-Myers Squibb,

2,

Abbott Immunology Pharmaceuticals, UCB,

5,

Abbott Immunology Pharmaceuticals,

8.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/role-of-particular-class-i-mhc-haplotypes-in-determining-different-traits-within-the-psoriatic-arthritis-phenotypes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology